Lucijanić, M., Livun, A., Tupek, K. M., Štoos Veić, T., Pejša, V. & Kušec, R. (2018). Higher Sclerostin/SOST expression is associated with lower percentage of circulatory blasts and better prognosis in patients with myelofibrosis. Annals of Hematology, 97. (7), 1293-1294. doi: 10.1007/s00277-018-3294-9
Lucijanić, Marko, et al. "Higher Sclerostin/SOST expression is associated with lower percentage of circulatory blasts and better prognosis in patients with myelofibrosis." Annals of Hematology, vol. 97, no. 7, 2018, pp. 1293-1294. https://doi.org/10.1007/s00277-018-3294-9
Lucijanić, Marko, Ana Livun, Katarina Marija Tupek, Tajana Štoos Veić, Vlatko Pejša and Rajko Kušec. "Higher Sclerostin/SOST expression is associated with lower percentage of circulatory blasts and better prognosis in patients with myelofibrosis." Annals of Hematology 97, no. 7 (2018): 1293-1294. https://doi.org/10.1007/s00277-018-3294-9
Lucijanić, M., et al. (2018) 'Higher Sclerostin/SOST expression is associated with lower percentage of circulatory blasts and better prognosis in patients with myelofibrosis', Annals of Hematology, 97(7), pp. 1293-1294. doi: 10.1007/s00277-018-3294-9
Lucijanić M, Livun A, Tupek KM, Štoos Veić T, Pejša V, Kušec R. Higher Sclerostin/SOST expression is associated with lower percentage of circulatory blasts and better prognosis in patients with myelofibrosis. Annals of Hematology [Internet]. 2018 July [cited 2024 November 22];97(7):1293-1294. doi: 10.1007/s00277-018-3294-9
M. Lucijanić, A. Livun, K. M. Tupek, T. Štoos Veić, V. Pejša and R. Kušec, "Higher Sclerostin/SOST expression is associated with lower percentage of circulatory blasts and better prognosis in patients with myelofibrosis", Annals of Hematology, vol. 97, no. 7, pp. 1293-1294, July 2018. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:105:406711. [Accessed: 22 November 2024]
